Skip to main content
SpringerLink
Log in

The importance of distinguishing “Clinical Judgement” in cancer management from “selection bias” in clinical trials

  • Editorial
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Eddy DM (1992) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10: 657–670

    PubMed  Google Scholar 

  • Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martine C, Laffranchi A, Valagussa P, Bonadonna G (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patiens with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169–1175

    PubMed  Google Scholar 

  • Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991). J Natl Cancer Inst 87: 1797–1805

    Google Scholar 

  • Karnofsky DA, Burchenal JH (1948) The clinical evaluation of chemotherapeutic agents in cancer.In Evaluation of chemotherapeutic agents, CM Macleod, Ed. New York, Columbia University Press, pp 191–205

    Google Scholar 

  • Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004–1013

    PubMed  Google Scholar 

  • Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao T-J, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L (1995) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575–2581

    PubMed  Google Scholar 

  • Simon R (1984) Importance of prognostic factors in cancer clinical trials. Cancer 68: 185–192

    Google Scholar 

  • Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 45: 2220–2224

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, Ohio, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. The importance of distinguishing “Clinical Judgement” in cancer management from “selection bias” in clinical trials. J Cancer Res Clin Oncol 122, 573–574 (1996). https://doi.org/10.1007/BF01221187

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01221187

Search

Navigation